

Revision date: 28-Jul-2011 Version: 1.1 Page 1 of 12

# IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Animal Health** Pfizer Inc 235 East 42nd Street New York, NY 10017

Poison Control Center Phone: 1-866-531-8896 Technical Services Phone: 1-800-366-5288

**Emergency telephone number:** 

CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd Ramsgate Road Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161

**Emergency telephone number:** 

ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: VMP Tablets

**Trade Name: VMP Tablets** 

Synonyms: Vitamin, Mineral, Protein Tablets

**Chemical Family:** Mixture

Intended Use: Veterinary product used as dietary supplement

## 2. HAZARDS IDENTIFICATION

Appearance: **Tablets** 

Non-hazardous in accordance with international standards for workplace safety. Statement of Hazard:

**Additional Hazard Information:** 

**Short Term:** May be harmful if swallowed. May be harmful if absorbed through the skin. (based on

components)

**EU Classification** 

**EU Indication of danger:** Not classified

**Australian Hazard Classification** 

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which Note:

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# **COMPOSITION/INFORMATION ON INGREDIENTS**

Hazard	lous
--------	------

Ingredient	CAS Number	EU EINECS/ELINCS List EU Classification	%
		<del>-</del>	

PZ01401

Material Name: VMP Tablets
Revision date: 28-Jul-2011
Page 2 of 12
Version: 1.1

3. COMPOSITION/INFORMATION (	ON INGREDIENTS			
AMORPHOUS SILICA	7631-86-9	231-545-4 418-260-2	Not Listed	*
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	Not Listed	*
Cholecalciferol (Vitamin D3)	67-97-0	200-673-2	T+;R26 T;R24/25 T;R48/25	<0.1
Cyanocobalamin (Vitamin B12)	68-19-9	200-680-0	Not Listed	*
Iron oxide	1309-37-1	215-168-2	Not Listed	*
Magnesium oxide	1309-48-4	215-171-9	Not Listed	*
Manganese carbonate	17375-37-0	241-414-3	Not Listed	*
Riboflavin (Vitamin B2)	83-88-5	201-507-1	Not Listed	*
Zinc oxide	1314-13-2	215-222-5	N;R50/53	<0.25

Ingredient	CAS Number	<b>EU EINECS/ELINCS List</b>	<b>EU Classification</b>	%
Biotin	58-85-5	200-399-3	Not Listed	*
Butylated hydroxyanisole	25013-16-5	246-563-8	Not Listed	*
Copper sulfate, anhydrous	7758-98-7	231-847-6	Not Listed	*
Flavor	NOT ASSIGNED	Not Listed	Not Listed	*
Folic Acid	59-30-3	200-419-0	Not Listed	*
Lecithin	8002-43-5	232-307-2	Not Listed	*
Niacinamide	98-92-0	202-713-4	Not Listed	*
Peanut Oil	8002-03-7	232-296-4	Not Listed	*
Pyridoxine Hydrochloride (Vitamin B6)	58-56-0	200-386-2	Not Listed	*
Taurine	107-35-7	203-483-8	Not Listed	*
Thiamine Mononitrate	532-43-4	208-537-4	Not Listed	*
Vitamin A Acetate	127-47-9	204-844-2	Not Listed	*
Vitamin E (D-alpha-Tocopherol)	59-02-9	200-412-2	Not Listed	*
Yeast, extract	8013-01-2	232-387-9	Not Listed	*
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

# 4. FIRST AID MEASURES

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

D704404

Material Name: VMP Tablets Page 3 of 12
Revision date: 28-Jul-2011 Version: 1.1

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

## 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

# 7. HANDLING AND STORAGE

General Handling: Avoid breathing dust, vapor or mist. Avoid contact with eyes, skin and clothing. When

handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA

filtration systems or other equivalent controls.

**Storage Conditions:** Store as directed by product packaging.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

#### **AMORPHOUS SILICA**

 Australia TWA
 2 mg/m³

 Austria OEL - MAKs
 4 mg/m³

 Czech Republic OEL - TWA
 0.1 mg/m³

 4.0 mg/m³

Estonia OEL - TWA 2 mg/m³
Germany - TRGS 900 - TWAs 4 mg/m³

**Germany (DFG) - MAK** 4 mg/m³ inhalable fraction

 Ireland OEL - TWAs
 6 mg/m³

 2.4 mg/m³

 Latvia OEL - TWA
 1 mg/m³

OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf Listed

Slovakia OEL - TWA 4.0 mg/m³
Slovenia OEL - TWA 4 mg/m³

Calcium phosphate dibasic, anhydrous

Latvia OEL - TWA 10 mg/m<sup>3</sup>

Material Name: VMP Tablets Page 4 of 12
Revision date: 28-Jul-2011 Version: 1.1

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

$C \cap$	nnar	sulfate.	anh	droue
CO	bbei	Sullate.	alliiv	/ui ous

ACGIH Threshold Limit Value (TWA) 1 mg/m<sup>3</sup> Finland OEL - TWA 1 mg/m<sup>3</sup>

## Iron oxide

ACGIH Threshold Limit Value (TWA)

Australia TWA

Austria OEL - MAKS

Belgium OEL - TWA

Denmark OEL - TWA

Estonia OEL - TWA

5 mg/m³

10 mg/m³

5 mg/m³

 Finland OEL - TWA
 5 mg/m³

 France OEL - TWA
 5 mg/m³

 Greece OEL - TWA
 10 mg/m³

 Hungary OEL - TWA
 6 mg/m³

 Ireland OEL - TWAs
 5 mg/m³

4 mg/m³
Lithuania OEL - TWA
3.5 mg/m³
OSHA - Final PELS - TWAS:
10 mg/m³
Poland OEL - TWA
5 mg/m³
Portugal OEL - TWA
5 mg/m³
Romania OEL - TWA
5 mg/m³
Slovakia OEL - TWA
1.5 mg/m³
Spain OEL - TWA
5 mg/m³

#### Magnesium oxide

Sweden OEL - TWAs

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Austria OEL - MAKS 5 mg/m³
10 mg/m³

 Belgium OEL - TWA
 10 mg/m³

 Bulgaria OEL - TWA
 10.0 mg/m³

 Czech Republic OEL - TWA
 5 mg/m³

 Denmark OEL - TWA
 6 mg/m³

 France OEL - TWA
 10 mg/m³

**Germany (DFG) - MAK**1.5 mg/m³ respirable fraction
4 mg/m³ inhalable fraction

Greece OEL - TWA 10 mg/m<sup>3</sup>

 5 mg/m³

 Hungary OEL - TWA
 6 mg/m³

 Ireland OEL - TWAs
 4 mg/m³

 5 mg/m³
 5 mg/m³

| 10 mg/m<sup>3</sup> | 4 mg/m<sup>3</sup> | OSHA - Final PELS - TWAs: | 15 mg/m<sup>3</sup> | 10 mg/m<sup>3</sup> | 10 mg/m<sup>3</sup> | Portugal OEL - TWA | 10 mg/m<sup>3</sup> | 10 mg/m

 $3.5 \text{ mg/m}^3$ 

Material Name: VMP Tablets Page 5 of 12
Revision date: 28-Jul-2011 Version: 1.1

#### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION 5 mg/m<sup>3</sup> Romania OEL - TWA 1.5 mg/m<sup>3</sup> Slovakia OEL - TWA 4 mg/m<sup>3</sup> Spain OEL - TWA 10 mg/m<sup>3</sup> **Niacinamide** Latvia OEL - TWA $1 \text{ mg/m}^3$ Lithuania OEL - TWA $1 \text{ mg/m}^3$ Riboflavin (Vitamin B2) $1 \text{ mg/m}^3$ Latvia OEL - TWA Lithuania OEL - TWA $1 \text{ mg/m}^3$ Zinc oxide **ACGIH Threshold Limit Value (TWA)** $2 \text{ mg/m}^3$ 10 mg/m<sup>3</sup> **ACGIH Threshold Limit Value (STEL) Australia STEL** 10 mg/m<sup>3</sup> **Australia TWA** 5 mg/m<sup>3</sup> 10 mg/m<sup>3</sup> 5 mg/m<sup>3</sup> **Austria OEL - MAKs Belgium OEL - TWA** 10 mg/m<sup>3</sup> 5 mg/m<sup>3</sup> 5.0 mg/m<sup>3</sup> **Bulgaria OEL - TWA** 2 mg/m<sup>3</sup> Czech Republic OEL - TWA **Denmark OEL - TWA** 4 mg/m<sup>3</sup> **Estonia OEL - TWA** 5 mg/m<sup>3</sup> $2 \text{ mg/m}^3$ **Finland OEL - TWA** 5 mg/m<sup>3</sup> France OEL - TWA 10 mg/m<sup>3</sup> Germany (DFG) - MAK 1 mg/m³ fume, respirable fraction **Greece OEL - TWA** 5 mg/m<sup>3</sup> 5 mg/m<sup>3</sup> **Hungary OEL - TWA Ireland OEL - TWAs** 5 mg/m<sup>3</sup> 0.5 mg/m<sup>3</sup> Latvia OEL - TWA 5 mg/m<sup>3</sup> Lithuania OEL - TWA **OSHA - Final PELS - TWAs:** 5 ma/m<sup>3</sup> 15 mg/m<sup>3</sup> **Poland OEL - TWA** 5 mg/m<sup>3</sup> 2 mg/m<sup>3</sup> Portugal OEL - TWA Romania OEL - TWA 5 mg/m<sup>3</sup> $1 \text{ mg/m}^3$ Slovakia OEL - TWA 5 mg/m<sup>3</sup> Slovenia OEL - TWA 5 mg/m<sup>3</sup> Spain OEL - TWA 10 mg/m<sup>3</sup> **Sweden OEL - TWAs** 5 mg/m<sup>3</sup> **Cholecalciferol (Vitamin D3)** Pfizer Occupational Exposure OEB 5 (control exposure to <1 ug/m³)

Pfizer Occupational Exposure OEB 3 (control exposure to the range of >10ug/m³ to < 100ug/m³)

Band (OEB):

Band (OEB):

P704404

**Folic Acid** 

Material Name: VMP Tablets

Revision date: 28-Jul-2011

Page 6 of 12

Version: 1.1

\_\_\_\_\_

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

# 10. STABILITY AND REACTIVITY

**Chemical Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

# 11. TOXICOLOGICAL INFORMATION

**General Information:** The information in this section describes the potential hazards of the individual ingredients and

the formulation.

Acute Toxicity: (Species, Route, End Point, Dose)

**Thiamine Mononitrate** 

Mouse Oral LD50 > 5000 mg/kg

Lecithin

Rat Oral LD50 > 8 ml/kg

**Cholecalciferol (Vitamin D3)** 

Rat Oral LD50 42 mg/kg

Mouse Sub-tenon injection (eye) LD 50 136 mg/kg

**Folic Acid** 

Mouse Oral LD 50 10 g/kg

Material Name: VMP Tablets Page 7 of 12
Revision date: 28-Jul-2011 Version: 1.1

# 11. TOXICOLOGICAL INFORMATION

#### Pyridoxine Hydrochloride (Vitamin B6)

Rat Oral LD 50 4 g/kg

### **Niacinamide**

LD50 Oral Rat 3500 mg/kg Mouse Oral LD50 2500 mg/kg Subcutaneous LD50 1680 g/kg ΙP LD50 2050 mg/kg Mouse Rabbit >2000 mg/kg Dermal LD 50

#### Vitamin E (D-alpha-Tocopherol)

Mouse Oral LD 50 >25 mL/kg

#### Vitamin A Acetate

Mouse Oral LD 50 4100 mg/kg

#### **Lactose Monohydrate**

Rat Oral LD 50 29700 mg/kg

### **Butylated hydroxyanisole**

Rat Oral LD50 2000 mg/kg Mouse Oral LD 50 1100 mg/kg Rat Intraperitoneal LD 50 881 mg/kg

## Zinc oxide

Mouse Oral LD50 7950 mg/kg
Rat IP LD50 240 mg/kg
Mouse Inhalation LD50 2500 mg/m³

Rat Oral LD 50 >5000 mg/kg

Nat Olai LD 30 >3000 II

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

# Irritation / Sensitization: (Study Type, Species, Severity)

#### **Peanut Oil**

Skin Irritation Rabbit Moderate

## Zinc oxide

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

## **Butylated hydroxyanisole**

12 Day(s) Rat Oral 3300 mg/kg LOAEL Liver, Blood

# Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

# **Cholecalciferol (Vitamin D3)**

Embryo / Fetal Development Rat Subcutaneous 90 mg/kg/day LOEL Teratogenic

### **Butylated hydroxyanisole**

Embryo / Fetal Development Rat Oral 30 g/kg LOEL Teratogenic

PZ01401

Material Name: VMP Tablets Page 8 of 12
Revision date: 28-Jul-2011 Version: 1.1

# 11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cholecalciferol (Vitamin D3)

In Vitro Bacterial Mutagenicity (Ames) Salmonella Negative

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) Negative

**Peanut Oil** 

Bacterial Mutagenicity (Ames) Salmonella Negative

**Butylated hydroxyanisole** 

In Vivo Micronucleus Bone Marrow Negative

In Vitro Bacterial Mutagenicity (Ames) Salmonella Negative

**Butylated hydroxyanisole** 

Two Year(s) Rat Oral 728 g/kg/day Gastrointestinal system, Tumors

Two Year(s) Rat Oral 874 g/kg/day Gastrointestinal system, Endocrine system, Tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

**AMORPHOUS SILICA** 

IARC: Group 3 (Not Classifiable)

Iron oxide

IARC: Group 3 (Not Classifiable)

**Butylated hydroxyanisole** 

IARC: Group 2B (Possibly Carcinogenic to Humans)

NTP: Reasonably Anticipated To Be A Human Carcinogen

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this mixture have not been fully evaluated. Releases to

the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Zinc oxide

Tadpole EC50 48 Hours 3.2 mg/L

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: VMP Tablets Page 9 of 12
Revision date: 28-Jul-2011 Version: 1.1

# 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

#### **OSHA Label:**

Non-hazardous in accordance with international standards for workplace safety.

#### Canada - WHMIS: Classifications

### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

# **AMORPHOUS SILICA**

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
231-545-4
418-260-2

Biotin

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
200-399-3

**Butylated hydroxyanisole** 

California Proposition 65 carcinogen initial date 1/1/90

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

246-563-8

Calcium phosphate dibasic, anhydrous

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

231-826-1

**Cholecalciferol (Vitamin D3)** 

Inventory - United States TSCA - Sect. 8(b) Present

Material Name: VMP Tablets
Revision date: 28-Jul-2011
Page 10 of 12
Version: 1.1

15. REGULATORY INFORMATION	
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 7
for Drugs and Poisons:	
EU EINECS/ELINCS List	200-673-2
Copper sulfate, anhydrous	
CERCLA/SARA Hazardous Substances	10 lb
and their Reportable Quantities:	4.54 kg
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 6
for Drugs and Poisons:	
EU EINECS/ELINCS List	231-847-6
Cyanocobalamin (Vitamin B12)	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-680-0
Folic Acid	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 2
for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	200-419-0
Iron oxide	ъ.
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-168-2
Lecithin	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present
obligations of Register:	roson
EU EINECS/ELINCS List	232-307-2
Magnesium oxide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-171-9
Manganese carbonate	
EU EINECS/ELINCS List	241-414-3
Niacinamide	
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-713-4
Peanut Oil	

Present

Inventory - United States TSCA - Sect. 8(b)

Material Name: VMP Tablets Page 11 of 12
Revision date: 28-Jul-2011 Version: 1.1

<b>15. REGULATORY INFORI</b>	MATION
------------------------------	--------

Australia (AICS): Present EU EINECS/ELINCS List 232-296-4

Pyridoxine Hydrochloride (Vitamin B6)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
200-386-2

Riboflavin (Vitamin B2)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS/ELINCS List

201-507-1

**Taurine** 

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

203-483-8

**Thiamine Mononitrate** 

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
208-537-4

Vitamin A Acetate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
204-844-2

Vitamin E (D-alpha-Tocopherol)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

200-412-2

Yeast, extract

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
232-387-9

Zinc oxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
215-222-5

**Lactose Monohydrate** 

Australia (AICS): Present

# 16. OTHER INFORMATION

### Text of R phrases mentioned in Section 3

R26 - Very toxic by inhalation.

Material Name: VMP Tablets Page 12 of 12
Revision date: 28-Jul-2011 Version: 1.1

R24/25 - Toxic in contact with skin and if swallowed.

R48/25 - Toxic: danger of serious damage to health by prolonged exposure if swallowed.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet** 

\_\_\_\_\_